David Swinney, CEO of iRND3, to Speak at Drug Design & Medicinal Chem Conf., May 8-10, 2013, Boston
David Swinney, CEO and Co-Founder of the Institute for Rare & Neglected Diseases Drug Discovery to Present at the 7th Drug Design & Medicinal Chemistry conference (May 8-10, 2013 in Boston, MA).
- San Francisco, CA (1888PressRelease) March 15, 2013 - Dr. David Swinney, CEO and Co-Founder of the Institute for Rare & Neglected Diseases Drug Discovery will give a featured presentation at GTC's 7th Drug Design & Medicinal Chemistry Conference on May 8-10, 2013 in Boston, MA.
One approach to drug design is to improve reversible equilibrium binding affinity to a target; however, in many cases, this approach does not take into account other molecular mechanisms of action (MMOA). Dr. Swinney will speak about MMOAs that include the dynamic molecular interactions involved in conformational changes and binding kinetics in his presentation, "Consideration of Molecular Mechanism of Action in Drug Design."
These MMOAs can help translate the information from binding to a selective pharmacological response. Furthermore, an optimal MMOA increases the therapeutic index of a medicine, and consequently, its usefulness.
Dr. Swinney will discuss why new approaches are needed in rational drug design in order to identify key dynamic conformational and kinetic features that will result in an optimal MMOA and thus an optimal therapeutic index.
David Swinney has devoted the majority of his career to the identification of effective mechanisms of drug action, promising leads and clinical candidates to address unmet medical needs. He has over 20 years of industrial experience (Roche, Syntex) and is currently CEO and Co-Founder of the non-profit, Institute for Rare & Neglected Diseases Drug Discovery (iRND3, www.irnd3.org).
GTC's 7th Drug Design & Medicinal Chemistry conference provides a forum for leaders from both industry and academia working in the fields of medicinal chemistry, computational chemistry, structural biology and related areas to review advances in established methods in drug discovery and discuss hot topics such as epigenetics, binding kinetics, data sharing and many more.
To view the conference agenda, click here.
To view the speaker list, click here.
The conference is part of the Drug Discovery Summit 2013, and will run parallel with three other exciting conferences:
Orphan Drugs Research and Commercialization
3rd Epigenetics in Drug Discovery
6th Imaging in Drug Discovery and Development
For more information, please visit www.gtcbio.com/drugdesign.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam